《藍籌業績》中生製藥(01177.HK)去年純利升427.2%至146.1億人幣 末期股息4港仙
中國生物製藥(01177.HK)公佈,截至去年12月底止全年收入按年增加13.6%至268.6億元人民幣(下同),純利大幅增長427.2%至146.1億元,基本盈利按年增長26.6%至29.3億元;每股盈利約77.83分。派末期息每股4港仙,連同首季及次季股息各派2港仙,全年共派股息每股8港仙。
去年度集團新產品銷售額121億元,按年增長34.3%,佔總收入增至45.1% ;抗腫瘤用藥之銷售額約92.16億元,按年增長21%,佔收入約34.3%;創新藥銷售額63.5億元,按年增長10.8%,收入佔比爲23.6%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.